Addressing safety issues—which drive roughly a quarter of all drug project failures—requires proactive management, especially when adverse events stem from off-target activity rather than primary pharmacology. Certara software powerfully tackles this challenge through Secondary Intelligence, an innovative in silico technology that transforms off-target screening data into quantitative predictions of clinical and in vivo safety outcomes. By assembling, curating, and visualizing comprehensive secondary pharmacology analyses, the platform helps researchers identify potential risks and rate them effectively. Ultimately, Certara empowers scientific teams to dial out dangerous side effects early, optimize safety profiles, and dramatically reduce project attrition.

Join for free to read